ABOUT THE COMPANY
Management
Anders Fugelli, PhD
Chariman and Chief Executive Officer
Anders Fugelli is Co-founder of Pharmasum Therapeutics. He has more than 20 years’ experience industrial R&D. He comes from a role as Head of Business Development in Norwegian start-up pharmaceuticals company Lytix Biopharma and has worked as Partner of life sciences and technology advisors, Amino AS. During the merger of GlaxoWellcome and SmithKlineBeecham, Anders was responsible, as Worldwide Assistant Director of Clinical Development and Product Strategy, of bringing together an overall company approach to the migraine field of the Neurology teams. Anders Fugelli is a Norwegian citizen.
Stig Jarle Pettersen, MSc
Chief Financial Officer
Stig Jarle Pettersen is engaged as CFO. He is a state authorized public accountant (Norway) educated from NHH, Norwegian School of Economics. He has worked as CFO in listed and private companies in Norway and Denmark and has broad experience from the pharmaceutical and biotech industry. In the last 4 years, he has worked as CFO for a portfolio of smaller R&D companies in the biotech and medtech sector. Stig Jarle Pettersen is a Norwegian citizen.
Wenche Marie Olsen, PhD
Chief Operating Officer
Wenche Marie Olsen has extensive operational experience in drug discovery and development through clinical phase 1 and 2 in large and small pharma companies. Her previous roles include Chief Operating Officer at Lytix Biopharma and Chief Executive Officer at Lauras. She has also held different positions in Nycomed Bioreg and as Partner in 4BIO. She received her PhD in biochemistry from the University of Oslo. Wenche Marie Olsen is a Norwegian citizen.
R&D Experts
Stephen Burbidge
VP Preclinical Development
Stephen has more than 20 years’ experience from Preclinical R&D Project Management within Neurosciences.
Mike Ashwood
VP CMC
Mike is an organic chemist in process chemistry with extensive industry experience in medicinal chemistry.
Isabel Gonzales
VP Biology
Isabel has broad experience in neuroscience and drug development from pharma industry.
Allison Morgan
VP Regul Affairs & Clinic
She has extensive experience within clinical programme design and regulatory strategy from pharmaceutical industry.
Board of Directors
Anders Fugelli, PhD
Chief Executive Officer
Anders Fugelli is Co-founder of Pharmasum Therapeutics. He has more than 20 years’ experience industrial R&D. He comes from a role as Head of Business Development in Norwegian start-up pharmaceuticals company Lytix Biopharma and has worked as Partner of life sciences and technology advisors, Amino AS. During the merger of GlaxoWellcome and SmithKlineBeecham, Anders was responsible, as Worldwide Assistant Director of Clinical Development and Product Strategy, of bringing together an overall company approach to the migraine field of the Neurology teams. Anders Fugelli is a Norwegian citizen.
Øystein Soug, MSc
Director
Øystein Soug is CEO of Oncoinvent and former CEO of Arxx Therapeutics (now Calluna Therapeutics) and listed company Targovax AS – a listed Norwegian biotech company. He has been the CFO of Algeta ASA, which was sold to Bayer AG for USD 2.9 billion in 2014. Prior to joining Algeta in 2008 Mr Soug worked for six years at Orkla, lastly as CFO of Orkla’s Russian division. Mr. Soug started his career as a banker with Credit Suisse and with the European Bank for Reconstruction and Development. He received an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997. Øystein Soug is a Norwegian citizen.
Tone Bjørnov
Director
Bjørnov has a degree within Business Administration form the Norwegian School of Management. Bjørnov is experienced, full time non-executive board director/chair of boards. Her core competencies are finance as well as good corporate governance and board work in general. She has broad experience within mergers, demergers, stock exchange listings, as well as building businesses.
John Sigurd Svendsen, PhD
Director
John Sigurd Svendsen brings extensive research experience from work in medical biochemistry, synthetic organic chemistry, and medicinal chemistry. He is a co-founder of the company. Previously, he was Head of the exploratory research in Lytix Biopharma. John received his PhD from the University of Tromsø and has been visiting scientist at several distinguished international institutions, including in the laboratory of Professor K. B. Sharpless (Nobel Laureate, Chemistry, 2000 and 2022) at Massachusetts Institute of Technology. He is a professor of organic chemistry in the Faculty of Sciences at the University of Tromsø. John Sigurd Svendsen is a Norwegian citizen.
Reijo Salonen, MD, PhD
Director
Salonen holds a PhD in neuroimmunology from Turku University and an MD with specialization in neurology from Turku University in Finland. Dr. Salonen has held senior positions in major pharmaceutical companies, serving as VP of Clinical Development and Product Strategy at GSK Neurology / GI, Global Head of Neurosciences Development at Pfizer and as Chief Medical Officer and SVP R&D at Orion Pharma. Reijo Salonen is a dual Finnish and US citizen.
News
August 12, 2024
As communicated to investors in June 2023, Pharmasum hereby reports the successful scale-up and isolation of crystalline material of their development candidate PST-674 at larger scale. Animal studies demonstrating robust PK have been undertaken, preparing for the entry into the next phases of development.
June 25, 2024
Tone Bjørnov was elected to the Board of Directors of Pharmasum Therapeutics.
June 28, 2023
Pharmasum Therapeutics closed a successful funding round with Folkeinvest.
June 28, 2023
Pharmasum Therapeutics closed a successful funding round with Folkeinvest.
September 27-29, 2022
Pharmasum Therapeutics presented at Nordic Life Science Days (NLSD).
July 19, 2022
Pharmasum Therapeutics announces the publication of an article titled “DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer’s Disease-Down Syndrome Phenotypes” in the journal Frontiers in Pharmacology.
https://www.frontiersin.org/articles/10.3389/fphar.2022.881385/full
February 15, 2022
Pharmasum Therapeutics has received support from the highly competitive Regional Research Fund for the project “A novel drug for treating dementia in Down syndrome».
December 16, 2021
Pharmasum Therapeutics presented at the annual DNB Healthcare Venture session.
November 17, 2021
Pharmasum Therapeutics announces the publication of an article titled “Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome” in the journal Pharmaceuticals.
November 11, 2021
Pharmasum Therapeutics has been selected to present at the DNB healthcare conference December 16, 2021.
October 24, 2021
Pharmasum Therapeutics announces the nomination the DYRK1A protein kinase inhibitor PST-674 as the development candidate.
February 23, 2021
Pharmasum Therapeutics AS announces the granting and publishing of its US patent covering composition of matter claims related to the Company’s ongoing DYRK1A inhibitor program.